Page 29 - RxExam's Naplex Theory Review Part-1

www.pharmacyexam.com Krisman

Dose Special Notes

Clevidipine Initial dose: 1-2 1). Patients who receive prolonged Clevidipine butyrate (Cleviprex)
(Injectable mg/hr. infusions and are not transitioned to other antihypertensive therapies
emulsion) should be monitored for the possibility of rebound hypertension for at
Maintenance: 4- least 8 hours after the infusion is stopped.
6 mg/hr.
2). Clevidipine is a single-use parenteral product that contains phospholipids
Maximum: 16 and can support microbial growth. Once the stopper is punctured, use
mg/hr. within 4 hours and discard any unused portion including that which is
currently being infused.

Nimodipine 60 mg PO every 1). Nimodipine (Nimotop) is indicated for the improvement of neurological
(Liquid filled 4 hour for 21 outcome by reducing the incidence and severity of ischemic deficits in
capsules) days; not less patients with subarachnoid hemorrhage from ruptured intracranial
than one hour berry aneurysms.
before or two
hours after 2). Nimodipine (Nimotop) has high lipid solubility. It is indicated for the
meals. improvement of neurological outcome by reducing the incidence and
severity of ischemic deficit in patients with subarachnoid hemorrhage
Therapy should or cerebral spasm. It dilates cerebral arteries and arterioles.
start within 96
hours of the 3). Do not administer Nimodipine (Nimotop) intravenously or by other
subarachnoid parenteral routes. Deaths and serious, life threatening adverse events
hemorrhage. have occurred when the contents of Nimodipine (Nimotop) capsules
have been injected parenterally.

Verapamil 80-120 mg PO 1). Verapamil (Calan) is indicated for the following:
(Tablet) T.I.D. a. Essential hypertension
(Tablet, ER) b. Chronic stable angina, vasospastic angina and unstable angina
(Capsule, ER) 200-400 mg PO c. In association with digitalis for the control of ventricular rate at rest
HS (ER). and during stress in patients with chronic atrial flutter and/or.
e. Prophylaxis of repetitive paroxysmal supraventricular tachycardia.

2). Prolonged therapy with Verapamil may produce severe constipation
problems in patients. Patients have to increase fluid intake and fiber
intake to prevent constipation.

3). The Covera-HS (Verapamil) formulation has been designed to initiate
the release of verapamil 4-5 hours after ingestion. This delay is introduced
by a layer between the active drug core and outer semipermeable
membrane. As water from the gastrointestinal tract enters the tablet,
this delay coating is solubilized and released. As tablet hydration continues,
the osmotic layer expands and pushes against the drug layer, releasing
drug through precision laser-drilled orifices in the outer membrane at a
constant rate. This controlled rate of drug delivery is independent of
posture, pH, gastrointestinal motility, and fed or fasting conditions.

28